New research suggests that patients who stop using popular weight-loss injections like semaglutide or tirzepatide tend to recover reduced body mass at a significantly accelerated pace than those who halt traditional lifestyle regimens.
Research printed in a major health publication demonstrates that while obese people often shed a large proportion of their total mass while undergoing treatment, the mass returns at an estimated rate of nearly a kilo each month once they quit.
"Users purchasing such drugs should be informed of the risk of quick weight regain when the therapy ends," stated expert Dr. Susan Jebb.
This pace of regain means a reversion to original weight within about 18 months.
Weighing Treatments
The research, which looked at 37 of studies involving thousands of patients, contrasted the outcomes of GLP-1 agonists with older methods.
Researchers emphasize that people who shed pounds through lifestyle changes alone generally have a more gradual weight regain—around 100 grams monthly—post-intervention.
Understanding the Fast Regain
Nutrition scientists suggest the mechanism of the injections explains the heightened rebound.
These medications imitate a natural hormone called glucagon-like peptide-1, which controls feelings of fullness.
"Artificially providing the hormone levels far above than the body's typical production might result in the system to produce less of its endogenous hormone, and could diminish sensitivity to its effects," noted Dr. Adam Collins, a nutrition specialist.
"Stopping of this hormone supplement means appetite is unsuppressed, making binge eating a significant risk."
An Ongoing Issue?
Medical guidelines recommend the jabs for people with weight-linked health risks, alongside prescribed lifestyle changes.
A number of clinicians contend that, considering the high risk of relapse, the treatment is often long-term.
This view is reinforced by pharmaceutical companies, who say that the findings "highlight the long-term nature of excess weight," akin to managing conditions like hypertension.
User Testimonies
Individuals who have discontinued the medication report a intense return of cravings.
"It felt as if a trigger flipping and you become starving," described one woman.
This difficulty is exacerbated if patients have not adopted lasting lifestyle or habit modifications during therapy.
Growing Use
Survey data indicate that millions of people in the UK have used these injections in the past year, with desire remaining high.
- Adoption is more common among women than males.
- The middle-aged age group shows the greatest level of interest.
- A large proportion access the drugs through private prescriptions rather than public health services.
Ultimately, clinicians emphasize that while GLP-1 drugs are potent agents for shedding pounds, they are not a permanent solution and maintained weight loss relies on ongoing behavioural changes.
